What are determinants of utilisation of pharmaceutical anticancer treatment during the last year of life in Norway? A retrospective registry study.
Christoffer BuggeStein KaasaErik Magnus SætherHans Olav MelbergIvar Sonbo KristiansenPublished in: BMJ open (2021)
The proportion of patients receiving PACT in Norway is lower than in several other industrialised countries. Age, type of cancer and area of living are significant determinants of variation in PACT.